Sign In
Buy CLSD
$0.410
+0 (+0%)
At Close: Mar 13, 2026
Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference
07:05am, Thursday, 01'st May 2025
ALPHARETTA, Ga., May 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the s
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
07:05am, Tuesday, 01'st Apr 2025
ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript
08:31pm, Thursday, 27'th Mar 2025
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Victor Chong - Chief Medical Officer Ch
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates
06:20pm, Thursday, 27'th Mar 2025
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.08 per share a year ago.
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
04:05pm, Thursday, 27'th Mar 2025
- Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner's New Drug Application for ARCATUS ® (XIPERE ® ) for Uveitic Macular
- Suprachoroidal Delivery Develops as Promising Mainstream Procedure for Treating Multiple Macular Diseases - - SCS Microinjector ® Provides Targeted and Compartmentalized Delivery of Therapeutics Di
- Post-Hoc Analyses Provide Comparative Data on Rescue Criteria and Intervention-Free Rates for Tyrosine Kinase Inhibitors (TKIs) in Wet AMD Development -
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025
07:05am, Wednesday, 12'th Mar 2025
ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of thera
- CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD - - Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other Ty
ALPHARETTA, Ga., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therap
- BCVA and CST Data from Sub-Group Analyses Provide Key Insights for Planned CLS-AX Phase 3 Trial Design - - BCVA and CST Data from Sub-Group Analyses Provide Key Insights for Planned CLS-AX Phase 3 T
Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference
07:05am, Tuesday, 04'th Feb 2025
ALPHARETTA, Ga., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
- Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial -
- ARCATUS ® , Branded as XIPERE ® in the U.S., is the First Globally Approved Suprachoroidal Therapy -
ALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
